Immune profiles and DNA methylation alterations related to non-muscle-invasive bladder cancer outcomes

Non-muscle-invasive bladder cancer (NMIBC) patients receive frequent monitoring because ≥ 70% will have recurrent disease. However, screening is invasive, expensive, and associated with significant morbidity making bladder cancer the most expensive cancer to treat per capita. There is an urgent need to expand the understanding of markers related to recurrence and survival outcomes of NMIBC. Our results expand on the knowledge of immune profiles and methylation alteration associated with NMIBC outcomes and represent a first step toward the development of DNA methylation-based biomarkers of tumor recurrence. Bisulphite converted DNA from white blood cells from 603 non-muscle-invasive bladder cancer patients, were hybridized to the Illumina Infinium HumanMethylationEPIC Beadchip v1.0_B4

非肌层浸润性膀胱癌（Non-muscle-invasive bladder cancer, NMIBC）患者需接受频繁的临床监测，因其至少70%会出现疾病复发。然而当前的筛查手段具有侵入性、成本高昂，且伴随显著的并发症风险，这使得膀胱癌成为人均治疗成本最高的恶性肿瘤。因此，学界亟需深化对与NMIBC复发及生存结局相关的标志物的认知。本研究结果拓展了学界对与NMIBC预后相关的免疫特征与甲基化改变的认知，同时为基于DNA甲基化的肿瘤复发生物标志物的开发迈出了第一步。本研究采集了603例NMIBC患者的白细胞来源亚硫酸氢盐转化DNA，并将其与Illumina Infinium HumanMethylationEPIC Beadchip v1.0_B4芯片进行杂交实验。